RU2008139625A - Композиции и способы лечения ревматоидного артрита - Google Patents
Композиции и способы лечения ревматоидного артрита Download PDFInfo
- Publication number
- RU2008139625A RU2008139625A RU2008139625/15A RU2008139625A RU2008139625A RU 2008139625 A RU2008139625 A RU 2008139625A RU 2008139625/15 A RU2008139625/15 A RU 2008139625/15A RU 2008139625 A RU2008139625 A RU 2008139625A RU 2008139625 A RU2008139625 A RU 2008139625A
- Authority
- RU
- Russia
- Prior art keywords
- compositions
- methods
- rheumatoid arthritis
- treating rheumatoid
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Abstract
1. Фармацевтическая композиция, содержащая VX-702 или его фармацевтически приемлемую соль. ! 2. Композиция по п.1, где указанная композиция содержит от примерно 1 до примерно 40 мг VX-702, от примерно 10 до примерно 20% двухосновного фосфата кальция, от примерно 10 до примерно 20% микрокристаллической целлюлозы, от примерно 0,1 до примерно 1,0% лаурилсульфата натрия, от примерно 0,1 до примерно 2,5% натрия кроскармеллозы, от примерно 0,0 до примерно 1% коллоидного диоксида кремния, от примерно 0,1 до примерно 5% стеарата магния и от примерно 10 до примерно 70% моногидрата лактозы.
Claims (2)
1. Фармацевтическая композиция, содержащая VX-702 или его фармацевтически приемлемую соль.
2. Композиция по п.1, где указанная композиция содержит от примерно 1 до примерно 40 мг VX-702, от примерно 10 до примерно 20% двухосновного фосфата кальция, от примерно 10 до примерно 20% микрокристаллической целлюлозы, от примерно 0,1 до примерно 1,0% лаурилсульфата натрия, от примерно 0,1 до примерно 2,5% натрия кроскармеллозы, от примерно 0,0 до примерно 1% коллоидного диоксида кремния, от примерно 0,1 до примерно 5% стеарата магния и от примерно 10 до примерно 70% моногидрата лактозы.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77986206P | 2006-03-07 | 2006-03-07 | |
| US60/779,862 | 2006-03-07 | ||
| US78027706P | 2006-03-08 | 2006-03-08 | |
| US60/780,277 | 2006-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008139625A true RU2008139625A (ru) | 2010-04-20 |
Family
ID=38475547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008139625/15A RU2008139625A (ru) | 2006-03-07 | 2007-03-07 | Композиции и способы лечения ревматоидного артрита |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070225339A1 (ru) |
| EP (1) | EP2026806A2 (ru) |
| JP (1) | JP2009529529A (ru) |
| KR (1) | KR20080100484A (ru) |
| AR (1) | AR062248A1 (ru) |
| AU (1) | AU2007223901A1 (ru) |
| BR (1) | BRPI0708645A2 (ru) |
| CA (1) | CA2644421A1 (ru) |
| CL (1) | CL2008002700A1 (ru) |
| IL (1) | IL193825A0 (ru) |
| MX (1) | MX2008011490A (ru) |
| NO (1) | NO20084190L (ru) |
| RU (1) | RU2008139625A (ru) |
| TW (1) | TW200808313A (ru) |
| WO (1) | WO2007103468A2 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010077119A (ja) * | 2008-08-25 | 2010-04-08 | Santen Pharmaceut Co Ltd | ウレイド基、アミノカルボニル基及び置換フェニル基を置換基として有するピロール誘導体を有効成分として含有する骨・関節疾患の予防又は治療剤 |
| WO2010038428A1 (ja) * | 2008-09-30 | 2010-04-08 | 武田薬品工業株式会社 | タキサン系抗がん剤の置き換え薬 |
| US20140128633A1 (en) * | 2008-12-31 | 2014-05-08 | Raymond A. Miller | Compositions containing nitro fatty acids |
| GB0908317D0 (en) * | 2009-05-14 | 2009-06-24 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
| CN102574781B (zh) | 2009-09-30 | 2014-02-19 | 东丽株式会社 | 2，3-二氢-1h-茚-2-基脲衍生物及其药物用途 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| WO2019071147A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1603878B1 (en) * | 2003-02-10 | 2013-01-02 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
| US20050192261A1 (en) * | 2003-09-15 | 2005-09-01 | Jost-Price Edward R. | Methods and reagents for the treatment of immunoinflammatory disorders |
| EP1691744A4 (en) * | 2003-11-13 | 2007-12-26 | Combinatorx Inc | METHOD AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES |
-
2007
- 2007-03-07 MX MX2008011490A patent/MX2008011490A/es not_active Application Discontinuation
- 2007-03-07 BR BRPI0708645-8A patent/BRPI0708645A2/pt not_active Application Discontinuation
- 2007-03-07 US US11/715,028 patent/US20070225339A1/en not_active Abandoned
- 2007-03-07 KR KR1020087024442A patent/KR20080100484A/ko not_active Application Discontinuation
- 2007-03-07 EP EP07752571A patent/EP2026806A2/en not_active Withdrawn
- 2007-03-07 AU AU2007223901A patent/AU2007223901A1/en not_active Abandoned
- 2007-03-07 AR ARP070100949A patent/AR062248A1/es unknown
- 2007-03-07 TW TW096107943A patent/TW200808313A/zh unknown
- 2007-03-07 WO PCT/US2007/005882 patent/WO2007103468A2/en active Application Filing
- 2007-03-07 CA CA002644421A patent/CA2644421A1/en not_active Abandoned
- 2007-03-07 JP JP2008558385A patent/JP2009529529A/ja not_active Withdrawn
- 2007-03-07 RU RU2008139625/15A patent/RU2008139625A/ru not_active Application Discontinuation
-
2008
- 2008-09-02 IL IL193825A patent/IL193825A0/en unknown
- 2008-09-11 CL CL2008002700A patent/CL2008002700A1/es unknown
- 2008-10-07 NO NO20084190A patent/NO20084190L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080100484A (ko) | 2008-11-18 |
| US20070225339A1 (en) | 2007-09-27 |
| AU2007223901A1 (en) | 2007-09-13 |
| WO2007103468A3 (en) | 2008-05-29 |
| CL2008002700A1 (es) | 2009-05-29 |
| CA2644421A1 (en) | 2007-09-13 |
| NO20084190L (no) | 2008-11-25 |
| EP2026806A2 (en) | 2009-02-25 |
| WO2007103468A2 (en) | 2007-09-13 |
| AR062248A1 (es) | 2008-10-29 |
| JP2009529529A (ja) | 2009-08-20 |
| MX2008011490A (es) | 2009-01-07 |
| IL193825A0 (en) | 2009-08-03 |
| TW200808313A (en) | 2008-02-16 |
| BRPI0708645A2 (pt) | 2011-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008139625A (ru) | Композиции и способы лечения ревматоидного артрита | |
| NO2020010I1 (no) | fostamatinib eller et farmasøytisk akseptabelt salt av fostamatinib, eller et hydrat, solvat eller N-oksid av fostamatinib eller det farmasøytisk akseptable saltet av fostamatinib, spesielt fostamatinib dinatrium, eventuelt på form av et hydrat | |
| UA97489C2 (ru) | Фармацевтическая композиция, которая содержит аморфный розувастатин кальция | |
| MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
| PT1940839E (pt) | Inibidores de piridopirimidinona pi3k alfa | |
| EA200800760A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| TW200734311A (en) | New compounds | |
| CA2505964A1 (en) | Pharmaceutical compositions and dosage forms of thalidomide | |
| WO2006041405A1 (en) | Substituted amino-pyrimidones and uses thereof | |
| TW200613306A (en) | Imidazotriazines as protein kinase inhibitors | |
| MXPA04004464A (es) | Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades. | |
| MY147390A (en) | Substituted isoindoles as bace inhibitors and their use | |
| UA100132C2 (en) | Isoxazolo-pyridine derivatives | |
| IL152916A0 (en) | Heteroaryl-phenyl heterobicyclic factor xa inhibitors | |
| LU91407I2 (fr) | Sunitinib optionnellement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel l-malate (sutent) | |
| HK1133596A1 (en) | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme | |
| RS51449B (sr) | Kombinacija aktivatora peroksizom proliferator-aktiviranog receptora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija | |
| MX2008001606A (es) | Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico. | |
| EA200701687A1 (ru) | Гидрохлорид аморфного лерканидипина | |
| NO20083836L (no) | N-hydroksyakrylamidforbindelser | |
| MX2007013468A (es) | Composiciones que contienen tanaproget micronizado. | |
| MXPA04008152A (es) | Compuestos azabiciclicos para el tratamiento de enfermedades. | |
| RU2008135718A (ru) | Композиции клопидогреля бисульфата | |
| TW200704633A (en) | Process for the preparation of sulfonamide derivatives | |
| HRP20050872A2 (en) | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100622 |